JP2000157289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000157289A5 JP2000157289A5 JP1999332033A JP33203399A JP2000157289A5 JP 2000157289 A5 JP2000157289 A5 JP 2000157289A5 JP 1999332033 A JP1999332033 A JP 1999332033A JP 33203399 A JP33203399 A JP 33203399A JP 2000157289 A5 JP2000157289 A5 JP 2000157289A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- present
- protein
- fragment
- adenoviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 description 78
- 239000012634 fragment Substances 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 33
- 150000007523 nucleic acids Chemical class 0.000 description 31
- 239000003981 vehicle Substances 0.000 description 31
- 108020004707 nucleic acids Proteins 0.000 description 29
- 102000039446 nucleic acids Human genes 0.000 description 29
- 101710145505 Fiber protein Proteins 0.000 description 25
- 238000001476 gene delivery Methods 0.000 description 25
- 210000000234 capsid Anatomy 0.000 description 23
- 230000005100 tissue tropism Effects 0.000 description 23
- 239000013598 vector Substances 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 20
- 238000004806 packaging method and process Methods 0.000 description 16
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 15
- 241000700605 Viruses Species 0.000 description 13
- 210000002889 endothelial cell Anatomy 0.000 description 13
- 239000000835 fiber Substances 0.000 description 9
- 210000003494 hepatocyte Anatomy 0.000 description 9
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 7
- 108090000565 Capsid Proteins Proteins 0.000 description 7
- 102100023321 Ceruloplasmin Human genes 0.000 description 7
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 101150076401 16 gene Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 101150117081 51 gene Proteins 0.000 description 1
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 241000701190 Human adenovirus 11 Species 0.000 description 1
- 241001428587 Human adenovirus 16 Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical group CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002095 anti-migrative effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98203921 | 1998-11-20 | ||
| EP98203921:6 | 1998-11-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000157289A JP2000157289A (ja) | 2000-06-13 |
| JP2000157289A5 true JP2000157289A5 (enExample) | 2009-10-22 |
| JP4683682B2 JP4683682B2 (ja) | 2011-05-18 |
Family
ID=8234363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP33203399A Expired - Fee Related JP4683682B2 (ja) | 1998-11-20 | 1999-11-22 | 平滑筋細胞および／または内皮細胞への組織向性を与えられた遺伝子送達ベクター |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JP4683682B2 (enExample) |
| AT (1) | ATE296894T1 (enExample) |
| AU (1) | AU770780B2 (enExample) |
| CA (1) | CA2318492C (enExample) |
| DE (1) | DE69925567T2 (enExample) |
| ES (1) | ES2244145T3 (enExample) |
| IL (1) | IL133032A (enExample) |
| MX (1) | MXPA99010682A (enExample) |
| NO (1) | NO995697L (enExample) |
| NZ (1) | NZ501214A (enExample) |
| WO (1) | WO2000031285A1 (enExample) |
| ZA (1) | ZA997213B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| CA2364499C (en) * | 1999-03-04 | 2008-12-23 | Introgene B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| JP2003534805A (ja) | 2000-05-31 | 2003-11-25 | ユニバーシティ オブ サスカチュワン | 変化した親和性を有する改変ウシアデノウイルス |
| EP1322774A2 (en) * | 2000-09-20 | 2003-07-02 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for dendritic cells |
| US7235233B2 (en) | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
| US6905678B2 (en) * | 2001-07-07 | 2005-06-14 | Crucell Holland B.V. | Gene delivery vectors with cell type specificity for mesenchymal stem cells |
| PT1497438E (pt) | 2002-04-25 | 2010-02-04 | Crucell Holland Bv | Meios e métodos para a produção de vectores de adenovírus |
| EP1482052A1 (en) * | 2003-05-27 | 2004-12-01 | Cytos Biotechnology AG | Modified polypeptides for targeting cell-entry of the adenoviruses of subtype B |
| NZ759833A (en) | 2017-05-26 | 2023-01-27 | Epicentrx Inc | Recombinant adenoviruses carrying transgenes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| DE69638058D1 (de) * | 1995-06-15 | 2009-11-26 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie |
| NZ323834A (en) * | 1995-11-28 | 2000-01-28 | Genvec Inc | Chimeric adenovirus coat protein vectors and methods for gene transfer to cells |
| US5877011A (en) * | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| FR2758822B1 (fr) * | 1997-01-30 | 1999-07-02 | Centre Nat Rech Scient | Utilisation d'un polypeptide a titre de recepteur cellulaire des adenovirus |
| FR2761689B1 (fr) * | 1997-04-02 | 1999-06-25 | Transgene Sa | Fibre adenovirale modifiee et adenovirus cibles |
-
1999
- 1999-11-18 IL IL133032A patent/IL133032A/en not_active IP Right Cessation
- 1999-11-19 ZA ZA9907213A patent/ZA997213B/xx unknown
- 1999-11-19 DE DE69925567T patent/DE69925567T2/de not_active Expired - Lifetime
- 1999-11-19 MX MXPA99010682A patent/MXPA99010682A/es not_active IP Right Cessation
- 1999-11-19 ES ES99203878T patent/ES2244145T3/es not_active Expired - Lifetime
- 1999-11-19 NO NO995697A patent/NO995697L/no not_active Application Discontinuation
- 1999-11-19 AT AT99203878T patent/ATE296894T1/de not_active IP Right Cessation
- 1999-11-22 WO PCT/NL1999/000717 patent/WO2000031285A1/en not_active Ceased
- 1999-11-22 JP JP33203399A patent/JP4683682B2/ja not_active Expired - Fee Related
- 1999-11-22 NZ NZ501214A patent/NZ501214A/en not_active IP Right Cessation
- 1999-11-22 AU AU59600/99A patent/AU770780B2/en not_active Ceased
- 1999-11-22 CA CA2318492A patent/CA2318492C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU696495B2 (en) | Adenoviral vectors of animal origin and use in gene therapy | |
| Eto et al. | PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability | |
| RU2219241C2 (ru) | Дефектный рекомбинантный аденовирусный вектор (варианты) | |
| Flotte | Gene therapy: the first two decades and the current state‐of‐the‐art | |
| JP2012139220A (ja) | 複製欠損アデノウイルスｔｎｆベクター | |
| JP2014516536A5 (enExample) | ||
| AU699867B2 (en) | Recombinant adenoviruses for gene therapy in cancers | |
| JP2000157289A5 (enExample) | ||
| CA2779632A1 (en) | Simian adenovirus and methods of use | |
| JPWO2018124181A1 (ja) | ｍＲＮＡの機能化方法 | |
| JP2003504004A (ja) | アデノウイルスベクター及び相同組換えイベントの低減方法 | |
| US6200798B1 (en) | Defective recombinant adenoviruses with inactivated IVa2 gene | |
| JP2003534805A5 (enExample) | ||
| Sintya et al. | Modifications in Adenoviral vectors to enhance its tropism: a literature review | |
| JP4951204B2 (ja) | 組換えアデノウイルスベクターとその応用 | |
| AU2001280006B2 (en) | Adenovirus vectors comprising introns | |
| JP7711050B2 (ja) | アデノウイルスベクターおよびその使用 | |
| US7264818B2 (en) | BAV packaging regions and E1 transcriptional control regions | |
| Grol et al. | Prospects of gene therapy for skeletal diseases | |
| WO2011066615A1 (en) | Methods and compositions for increasing titer of recombinant porcine adenovirus-3 vectors |